CD1D and Miyoshi myopathy: Overall, these data demonstrate that CD1d is expressed by the majority of patient-derived MM, (myelo)monocytic AML, and CLL cells and that CD1d-Vδ2 hu-bsTCE strongly enhanced type 1 NKT and Vγ9Vδ2-T cell activation, resulting in robust cytotoxic responses toward these cells.